Clinical ease of using doxazosin in BPH patients with and without hypertension

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 2, 2005, Pages 152-157

  Steers, W D ^a   Kirby, R S ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

1 adrenoceptor antagonists; Benign prostatic hyperplasia; Blood pressure; Doxazosin

Indexed keywords

ANTIHYPERTENSIVE AGENT; DOXAZOSIN; PLACEBO; TAMSULOSIN;

BLOOD PRESSURE REGULATION; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DOXAZOSIN; HUMANS; HYPERTENSION; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 23944513897     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500787     Document Type: Review

References (42)

1. Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging 1997; 10: 349-366.
2. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307.
3. James S et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142 (2, Part 1): 438.
4. Barry MJ et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia, J Urol 1993; 150 (2, Part 1): 351-358.
5. Sciarra A et al. Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia. Prostate 1998; 34: 121-128; discussion 129.
6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-471.
7. Andersson KE. The concept of uroselectivity. Eur Ural 1998; 33 (Suppl 2): 7-11.
8. Kirby R, Andersson KE, Lepor H, Steers WD. Alpha(1)-adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer P D 2000; 3: 76-83.
9. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs cooperative study. J Urol 2000; 163: 1134-1137.
10. He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997; 81: 1077-1097.
11. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 495-507.
12. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 1995; 168: 7-12.
13. Davey MJ. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension. Am J Med 1989; 87: 36S-44S.
14. Fulton B, Wagstaff A, Sorkin E. Doxagosin. Ah update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
15. Chung M et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-687.
16. Lemmer B, Nold G. Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension. Blood Press Monit 2003; 8: 119-125.
17. Anegon M et al. A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. Clin Ther 2002; 24: 786-797.
18. Lund-Johansen P, Kirby RS. Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: A review of hypertension and BPH studies. Blood Press 2003; 12 (Suppl 1): 5-13.
19. Jimenez-Garcia R et al. Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients. Int J Clin Pract 2003; 57: 267-272.
20. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. J Cardiovasc Pharmacol 1999; 33: 791-797.
21. Kirby RS et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001, 87: 192-200.
22. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-409.
23. Gratzke P, Kirby RS. [Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily]. MMW Fortschr Med 2000; 142: 40.
24. Kirby RS. Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 182-186.
25. Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: The Hypertension and BPH Intervention Trial (HABIT). Clin Ther 1999; 21: 1732-1748.
26. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571.
27. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89: 1545-1556.
28. Gillenwater JY et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115.
29. Fawzy A, Hendry A, Cook E, Gonzalez F. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. Int J Urol 1999; 6: 346-354.
30. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press 1999; 8: 184-191.
31. Calvo C, Gil-Extremera B, Gomez-Fernanzez P, Masramon X. Doxazosin GITS 4mg vs doxazosin-S 2mg and 4mg for stage 1 to stage 2 HTN (Abstract P-196). Am J Hypertens 2003; 16 (5, Part 2): 110A.
32. Anlauf M et al. Amblante 24-Stunden-Blutdruckmessung (ABPM). Dtsch Med Wochenschr 1998; 123: 1426-1430.
33. Calvo C et al. Dose and administration-time dependent effects of doxazosin GITS on 24-hour blood pressure in patients with refractory hypertension (Abstract P-194). Am J Hypertens 2003; 16 (5, Part 2): 109A.
34. Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: A pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28: 223-228.
35. Fawzy A et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 1995; 154: 105-109.
36. Kaplan SA, D'Alisera PM. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: A pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 1998; 53: M201-M206.
37. Kaplan SA, Meade-D'Alisera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: 512-517.
38. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91: 41-44.
39. Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl 1994; 74: 13-17.
40. Alabaster VA, Davey MJ. The alpha 1-adrenoceptor antagonist profile of doxazosin: Preclinical pharmacology. Br J Clin Pharmacol 1986; 21 (Suppl 1): 9S-17S.
41. Lund-Johansen P, Omvik P, Haugland H. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. Br J Clin Pharmacol 1986; 21 (Suppl 1): 45S-54S.
42. Takata Y et al. Doxazosin and 48-hour ambulatory blood pressure monitoring in normotensive subjects. Jpn Circ J 1994; 58: 403-408.